FOLH1 and nonpapillary renal cell carcinoma: These findings suggest that PSMA PET imaging could serve as a noninvasive diagnostic modality to guide CST selection (IO/IO vs. IO/VEGFi) and predict responses to VEGFi treatments in m-ccRCC [39].